Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma.

Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma.
复制标题

DOI:
10.3390/pharmaceutics14112429
复制
发表时间:
2022-11-10
期刊:
影响因子:
5.4
通讯作者:
Heller, Richard
Heller, Richard
中科院分区:
医学2区
文献类型:
--
作者:
Shi, Guilan;Scott, Megan;Mangiamele, Cathryn G.;Heller, Richard

文献摘要

参考文献

相似文献

抵抗检查站封锁治疗是临床上的一项挑战。原发和获得性耐药都已成为主要障碍,极大地限制了阻断疗法的长效和广泛应用。许多转移性黑色素瘤患者最终需要进一步治疗。肿瘤部位缺乏T细胞的渗透是限制免疫检查点抑制剂疗效的一个公认的因素。在本研究中,我们在转移性B16F10黑色素瘤模型中联合瘤内注射IL-12、电转移和抗PD-1,以增加肿瘤浸润性淋巴细胞,提高治疗效果。我们发现,有效的抗肿瘤反应需要肿瘤浸润性CD8+和CD4+T细胞的亚群。此外,联合治疗诱导肿瘤细胞表面更高的MHC-I表达,从而阻碍肿瘤细胞逃避免疫识别。此外,我们发现通过暴露于IL-12来激活T细胞会导致对抗PD-1治疗敏感的肿瘤,这提示了一种改善对检查点封锁的反应的治疗策略。
Resistance to checkpoint-blockade treatments is a challenge in the clinic. Both primary and acquired resistance have become major obstacles, greatly limiting the long-lasting effects and wide application of blockade therapy. Many patients with metastatic melanoma eventually require further therapy. The absence of T-cell infiltration to the tumor site is a well-accepted contributor limiting immune checkpoint inhibitor efficacy. In this study, we combined intratumoral injection of plasmid IL-12 with electrotransfer and anti-PD-1 in metastatic B16F10 melanoma tumor model to increase tumor-infiltrating lymphocytes and improve therapeutic efficacy. We showed that effective anti-tumor responses required a subset of tumor-infiltrating CD8+ and CD4+ T cells. Additionally, the combination therapy induced higher MHC-I surface expression on tumor cells to hamper tumor cells escaping from immune recognition. Furthermore, we found that activating T cells by exposure to IL-12 resulted in tumors sensitized to anti-PD-1 treatment, suggesting a therapeutic strategy to improve responses to checkpoint blockade.
CTLA-4 阻断和 4-1BB 激活相结合,通过增加 T 细胞浸润、增殖和细胞因子产生来增强肿瘤排斥。
DOI: 10.1371/journal.pone.0019499
发表时间: 2011-04-29
期刊: PloS one
影响因子: 3.7
作者:
Curran MA;Kim M;Montalvo W;Al-Shamkhani A;Allison JP
通讯作者: Allison JP
DOI: 10.1177/1178223417731565
发表时间: 2017
期刊: Breast cancer : basic and clinical research
影响因子: --
作者:
Cohen IJ;Blasberg R
通讯作者: Blasberg R
DOI: 10.4049/jimmunol.164.2.916
发表时间: 2000-01-15
影响因子: 4.4
作者:
Dobrzanski, MJ;Reome, JB;Dutton, RW
通讯作者: Dutton, RW
DOI: 10.1038/bjc.2015.101
发表时间: 2015-04-28
影响因子: 8.8
作者:
Abiko, K.;Matsumura, N.;Hamanishi, J.;Horikawa, N.;Murakami, R.;Yamaguchi, K.;Yoshioka, Y.;Baba, T.;Konishi, I.;Mandai, M.
通讯作者: Mandai, M.
DOI: 10.1016/j.celrep.2017.04.031
发表时间: 2017-05-09
期刊: Cell reports
影响因子: 8.8
作者:
Garcia-Diaz A;Shin DS;Moreno BH;Saco J;Escuin-Ordinas H;Rodriguez GA;Zaretsky JM;Sun L;Hugo W;Wang X;Parisi G;Saus CP;Torrejon DY;Graeber TG;Comin-Anduix B;Hu-Lieskovan S;Damoiseaux R;Lo RS;Ribas A
通讯作者: Ribas A